
B/m/vinci8/data1/riedel/corpora/nyt/nyt/data/2005/05/07/1670568.xmlê


ADTO

bookwormNNO

sinceINO

	childhoodNNO
	
,,O

SusanNNPPERSON

Desmond-HellmannNNPPERSON

saysVBZO

thatINO

shePRPO

copedVBDO

withINO

jobNNO

anxietyNNO

earlierRBRO

thisDTO

yearNNO

byINO

readingVBGO
	
..O?ÇÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000006ab6d52 *PERSON‰

ShePRPO

poredVBDO

overINO

theDTO

resultsNNSO

ofINO

oldJJO

clinicalJJO

trialsNNSO

ofINO

herPRP$O

companyNNO

'sPOSO

drugsNNSO
	
,,O

tryingVBGO

toTOO

reassureVBO

herselfPRPO

thatINO

threeCDO

	importantJJO

newJJO

trialsNNSO

wouldMDO

turnVBO

outRPO

allRBO

rightJJO
	
..O

''''Oµ

IPRPO

justRBO

keptVBDO

goingVBGO

backRBO

andCCO

	rereadingVBGO

themPRPO
	
,,O

''''O

saidVBDO

Dr.NNPPERSON

Desmond-HellmannNNPPERSON
	
,,O

theDTO

	presidentNNO

forINO

productNNO

developmentNNO

atINO

	GenentechNNPORGANIZATION
	
,,O

theDTO

bigJJO

biotechnologyNNO

companyNNO
	
..O

''''OEÉÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATIONÑÄÄÄ¯ˇˇˇˇ *PERSON∑

ItPRPO

'sVBZO

	importantJJO

toTOO

beVBO

data-drivenJJO

andCCO

notRBO

tooRBO


optimisticJJO
	
..O

''''Oy

HerPRP$O

	attentionNNO

toTOO

dataNNSO

hasVBZO

paidVBNO

offRPO
	
..Oª

InINO

theDTO

lastJJO

twoCDO

monthsNNSO
	
,,O

	GenentechNNPORGANIZATION

hasVBZO

reportedVBNO


remarkableJJO

successNNO

inINO

allDTO

threeCDO

trialsNNSO
	
,,O

	involvingVBGO

twoCDO

ofINO

itsPRP$O

cancerNNO

drugsNNSO
	
..OEÖÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATIONô

TheDTO

	successesNNSO

followVBPO


aDTO

17-monthJJO

periodNNO

endedVBNO

lateRBRO

lastJJO

yearNNO

inINO

whichWDTO

theDTO

companyNNO

hadVBDO

fourCDO

newJJO

drugsNNSO

approvedVBNO

byINO

theDTO

FoodNNPORGANIZATION

andCCORGANIZATION

DrugNNPORGANIZATION
#
AdministrationNNPORGANIZATION
	
,,O


aDTO

notableJJO

hotJJO

streakNNO

inINO

theDTO

drugNNO

industryNNO
	
..OEÜÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000018a7c *ORGANIZATION∏

AtINO


aDTO

timeNNO

whenWRBO

manyJJO

pharmaceuticalJJO

	companiesNNSO

areVBPO

flailingVBGO

inINO

theirPRP$O

effortsNNSO

toTOO

developVBO

drugsNNSO


--:O


aDTO

majorJJO

factorNNO

inINO

theDTO

abruptJJO

resignationNNO

onINO

ThursdayNNPO

ofINO

MerckNNPPERSON

'sPOSO

chiefJJO

	executiveNNO
	
,,O

RaymondNNPPERSON

V.NNPPERSON

	GilmartinNNPPERSON


--:O

	GenentechNNPORGANIZATION

hasVBZO

becomeVBNO


aDTO

modelNNO

ofINO


innovationNNO

andCCO


aDTO

leadingJJO

supplierNNO

ofINO

cancerNNO

drugsNNSO
	
..OEáÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1# #*ORGANIZATIONàÄÄÄ¯ˇˇˇˇ !*PERSONâÄÄÄ¯ˇˇˇˇ *PERSON˚

AndCCO

	GenentechNNPORGANIZATION


executivesNNSO

andCCO

outsideJJO

analystsNNSO

sayVBPO

muchJJO

ofINO

theDTO

creditNNO

goesVBZO

toTOO

Dr.NNPPERSON

Desmond-HellmannNNPPERSON
	
,,O

whoWPO

runsVBZO

theDTO

companyNNO

'sPOSO

clinicalJJO

trialsNNSO
	
..OäÄÄÄ¯ˇˇˇˇ *PERSONEãÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATION“


ADTO

cancerNNO


specialistNNO

byINO

trainingNNO

whoWPO

isVBZO


invariablyRBO

	describedVBNO

asINO

smartJJO
	
,,O

friendlyJJO
	
,,O

level-headedJJO

andCCO

attunedVBNO

toTOO

theDTO

feelingsNNSO

ofINO

patientsNNSO
	
,,O

shePRPO

isVBZO

oneCDO

ofINO

theDTO

fewJJO

womenNNSO

inINO

theDTO

	uppermostJJO

echelonsNNSO

ofINO

theDTO

pharmaceuticalJJO

businessNNO

andCCO

onINO

FortuneNNPO

magazineNNO

'sPOSO

listNNO

ofINO

theDTO

50CDO

mostRBSO

powerfulJJO

womenNNSO

inINO

businessNNO
	
..O

''''OÊ

NotRBO

manyJJO

peopleNNSO

canMDO

sayVBO
	
,,O


```O

IPRPO

'veVBPO

madeVBNO

myPRP$O

markNNO

savingVBGO

peopleNNSO

'sPOSO

livesNNSO
	
,,O

growingVBGO

theDTO

worldNNO

'sPOSO

biggestJJSO

biotechnologyNNO

companyNNO

andCCO

peopleNNSO

stillRBO

likeINO

mePRPO
	
,,O

''''O


'''O

saidVBDO

KurtNNPPERSON

vonNNPPERSON

EmsterNNPPERSON
	
,,O


aDTO

partnerNNO

atINO

MPMNNPORGANIZATION

CapitalNNPORGANIZATION
	
,,O


aDTO

biotechnologyNNO


investmentNNO

companyNNO
	
..OEåÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000005f210c5( )*ORGANIZATIONçÄÄÄ¯ˇˇˇˇ! #*PERSON…

WithINO

theDTO

companyNNO

'sPOSO

recentJJO

	successesNNSO

inINO

clinicalJJO

trialsNNSO
	
,,O

theDTO

66CDO

percentNNO

increaseNNO

inINO

	GenentechNNPORGANIZATION

'sPOSO

stockNNO

priceNNO

sinceINO

	mid-MarchNNO

hasVBZO

madeVBNO

itPRPO

theDTO

mostRBSO

highlyRBO

valuedVBNO

biotechnologyNNO

companyNNO
	
..OEéÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATION‹

ItPRPO

stillRBO

trailsVBZO

AmgenNNPORGANIZATION

inINO

revenueNNO
	
::O
	
$$O

4.6CDO

billionCDO

lastJJO

yearNNO
	
,,O

comparedVBNO

withINO

AmgenNNPORGANIZATION

'sPOSO
	
$$O

10.6CDO

billionCDO
	
..OEèÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000003ba040 *ORGANIZATIONEêÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000003ba040 *ORGANIZATION™

ButCCO

	GenentechNNPORGANIZATION

'sPOSO
	
$$O

77.2CDO

billionCDO

marketNNO

capitalizationNNO

isVBZO

nowRBO

slightlyRBO

higherJJRO

thanINO

thatDTO

ofINO

MerckNNPLOCATION
	
,,O


aDTO

conventionalJJO

drugNNO

companyNNO

withINO

fiveCDO

timesNNSO

theDTO

revenueNNO

thatWDTO

wasVBDO

onceRBO

theDTO

paragonNNO

ofINO

pharmaceuticalJJO


innovationNNO
	
..OëÄÄÄ¯ˇˇˇˇ *LOCATIONEíÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATIONë

Dr.NNPPERSON

Desmond-HellmannNNPPERSON
	
,,O

47CDO
	
,,O

	deflectedVBNO

anyDTO

praiseNNO

andCCO

creditedVBDO

herPRP$O

wholeJJO

companyNNO
	
..O

''''OìÄÄÄ¯ˇˇˇˇ  *PERSON®

IPRPO

haveVBPO

toTOO

sayVBO

IPRPO

'mVBPO

humbledVBNO

byINO

allDTO

theDTO

successNNO
	
,,O

''''O

shePRPO

saidVBDO

thisDTO

weekNNO

inINO

anDTO

	interviewNNO

atINO

	GenentechNNPORGANIZATION

'sPOSO

	sprawlingNNO

andCCO

	expandingVBGO

campusNNO

overlookingVBGO

SanNNPLOCATION

	FranciscoNNPLOCATION

BayNNPLOCATION
	
..O

''''OAîÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000003573c *LOCATIONEïÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATIONg

ItPRPO

makesVBZO

mePRPO

moreJJRO

anxiousJJO
	
..O

''''Oâ

ButCCO

shePRPO

isVBZO

notRBO

soRBO

humbleJJO

aboutINO

	GenentechNNPORGANIZATION

'sPOSO

	ambitionsNNSO
	
..O

''''OEñÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATIONç

OneCDO

ofINO

ourPRP$O

goalsNNSO

isVBZO

toTOO

rewriteVBO

theDTO

medicalJJO

	textbooksNNSO
	
,,O

''''O

shePRPO

saidVBDO
	
,,O

byINO

	producingVBGO

drugsNNSO

''''O

soINO

revolutionaryJJO
	
,,O

soRBO

	differentJJO
	
,,O

thatINO

youPRPO

haveVBPO

toTOO

getVBO

yourPRP$O

eraserNNO

outRPO
	
..O

''''O¶

SoRBO

farRBO

theDTO

companyNNO

hasVBZO

doneVBNO

thatINO

inINO

treatingVBGO

cancerNNO
	
..O”

RituxanNNPPERSON
	
,,O

forINO

non-HodgkinJJO

'sJJO

lymphomaNNO
	
,,O

	developedVBNO

withINO

Biogen-IdecNNPO
	
,,O

approvedVBDO

inINO

1997CDO
	
,,O

wasVBDO

theDTO

firstJJO

cancerNNO

drugNNO

usingVBGO


aDTO


technologyNNO

calledVBNO


monoclonalJJO


antibodiesNNSO
	
..OóÄÄÄ¯ˇˇˇˇ   *PERSON°

ItPRPO

hasVBZO

becomeVBNO

theDTO

worldNNO

'sPOSO

best-sellingJJO

cancerNNO

medicineNNO
	
..OÙ

	HerceptinNNPPERSON
	
,,O

forINO

breastNNO

cancerNNO
	
,,O

isVBZO

theDTO

exemplarNNO

ofINO

	so-calledJJO

personalizedJJO

therapyNNO


--:O

aimedVBNO

atINO

theDTO

25CDO

percentNNO

ofINO

patientsNNSO

whoseWP$O

tumorsNNSO

haveVBPO


aDTO


particularJJO

geneticJJO

characteristicNNO
	
..OòÄÄÄ¯ˇˇˇˇ   *PERSON†

AndCCO

AvastinNNPPERSON
	
,,O

approvedVBDO

forINO

colonNNO

cancerNNO
	
,,O

isVBZO

theDTO

firstJJO

approvedVBNO

cancerNNO

drugNNO

thatWDTO

worksVBZO

byINO

chokingVBGO

offRPO

theDTO

bloodNNO

supplyNNO

toTOO

tumorsNNSO
	
..OôÄÄÄ¯ˇˇˇˇ *PERSON˛

TwoCDO

ofINO

theDTO

recentJJO


successfulJJO

trialsNNSO

showedVBDO

itPRPO

alsoRBO

workedVBDO

againstINO

lungNNO

andCCO

breastNNO

cancerNNO
	
..O¸

TheDTO

thirdJJO

recentJJO

trialNNO
	
,,O

actuallyRBO

twoCDO

trialsNNSO

combinedVBNO
	
,,O

showedVBDO

thatINO

	HerceptinNNPPERSON
	
,,O

nowRBO

usedVBNO

forINO

advancedJJO

breastNNO

cancerNNO
	
,,O

alsoRBO

worksVBZO

atINO

anDTO

earlierJJRO

stageNNO

ofINO

theDTO

diseaseNNO
	
..OöÄÄÄ¯ˇˇˇˇ *PERSON‰

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

saidVBDO

thatINO

insideINO

	GenentechNNPLOCATION
	
,,O

littleJJO

	attentionNNO

isVBZO

paidVBNO

toTOO

herPRP$O

genderNNO
	
..OAõÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *LOCATIONúÄÄÄ¯ˇˇˇˇ  *PERSONƒ

ShePRPO

andCCO

anotherDTO

femaleJJO

	executiveNNO
	
,,O

MyrtleNNPPERSON

S.NNPPERSON

PotterNNPPERSON
	
,,O

theDTO

	presidentNNO

forINO


commercialJJO


operationsNNSO
	
,,O

areVBPO

onINO

theDTO


six-memberJJO

	executiveJJO

	committeeNNO
	
..O?ùÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000060bbbf8 *PERSONò

AndCCO

theyPRPO

areVBPO

co-chairwomenNNSO

ofINO

theDTO

companyNNO

'sPOSO

powerfulJJO

	portfolioNNORGANIZATION

reviewNNORGANIZATION

	committeeNNORGANIZATION
	
..OûÄÄÄ¯ˇˇˇˇ	 *ORGANIZATION˙

TheDTO

reviewNNO

panelNNO

meetsVBZO

forINO

anDTO

entireJJO

dayNNO

onceRBO


aDTO

monthNNO

toTOO

makeVBO

	decisionsNNSO

onINO

whichWDTO

drugsNNSO

toTOO

pursueVBO

andCCO

howWRBO

toTOO

developVBO

themPRPO
	
..Oå

TheDTO

	committeeNNO

hasVBZO

membersNNSO

fromINO

allDTO

partsNNSO

ofINO

	GenentechNNPLOCATION


--:O

researchNNO
	
,,O

developmentNNO
	
,,O

	marketingNNO
	
,,O

financeNNO

andCCO

legalJJO


--:O

andCCO

eachDTO

drugNNO

	candidateNNO

isVBZO

givenVBNO

	numericalJJO

valuesNNSO

basedVBNO

onINO

itsPRP$O

chanceNNO

ofINO

successNNO

inINO

clinicalJJO

trialsNNSO
	
,,O

itsPRP$O

	potentialJJO

salesNNSO

andCCO

soRBO

onINO
	
..OAüÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *LOCATIONö

OpinionsNNSO

areVBPO

soughtVBNO

fromINO

thoseDTO

whoWPO

knowVBPO

bestJJSO
	
..O

''''O

ItPRPO

'sVBZO

notRBO

peopleNNSO

tellingVBGO

youPRPO

whatWPO

toTOO

doVBO
	
;:O

theyPRPO

askVBPO

youPRPO

whatWPO

youPRPO

thinkVBPO
	
,,O

''''O

saidVBDO

Dr.NNPPERSON

Desmond-HellmannNNPPERSON
	
..O†ÄÄÄ¯ˇˇˇˇ *PERSONÌ

ShePRPO

recalledVBDO

thatINO

asINO


aDTO

newcomerNNO

andCCO

juniorJJO


researcherNNO

atINO

	GenentechNNPORGANIZATION

inINO

1995CDO
	
,,O

shePRPO

wasVBDO

shockedVBNO

whenWRBO

ArthurNNPPERSON

D.NNPPERSON

LevinsonNNPPERSON
	
,,O

thenRBO

theDTO

headNNO

ofINO

researchNNO

andCCO

nowRBO

chiefJJO

	executiveNNO
	
,,O

askedVBDO

forINO

herPRP$O

opinionNNO
	
..O

''''O?°ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000a9f005 *PERSONE¢ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1
 
*ORGANIZATION„

ThatDTO

wasVBDO

soRBO

	differentJJO

fromINO

whatWPO

IPRPO

hadVBDO

experiencedVBNO

beforeRBO
	
,,O

''''O

shePRPO

saidVBDO
	
..OÚ

ItPRPO

wasVBDO

	attentionNNO

toTOO

dataNNSO

thatWDTO

ledVBDO

Dr.NNPPERSON

LevinsonNNPPERSON

andCCO

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

toTOO

stickVBO

withINO

AvastinNNPPERSON

threeCDO

yearsNNSO

agoRBO
	
,,O

evenRBO

afterINO

itPRPO

failedVBDO

inINO

itsPRP$O

firstJJO

bigJJO

trialNNO

andCCO

manyJJO

peopleNNSO

onINO

WallNNPO

StreetNNPO

wereVBDO

givingVBGO

upRPO

onINO

theDTO

drugNNO
	
..O£ÄÄÄ¯ˇˇˇˇ *PERSON§ÄÄÄ¯ˇˇˇˇ
 *PERSON•ÄÄÄ¯ˇˇˇˇ *PERSONÎ

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

saidVBDO

carefulJJO

analysisNNO

ofINO

theDTO

trialNNO
	
,,O

andCCO

ofINO

earlierJJRO

onesNNSO
	
,,O

showedVBDO

theDTO

drugNNO

hadVBDO

someDTO

effectNNO
	
..O¶ÄÄÄ¯ˇˇˇˇ  *PERSONÊ

AsINO


aDTO


relativelyRBO

smallJJO

companyNNO

ofINO

8,000CDO

	employeesNNSO
	
,,O

	GenentechNNPORGANIZATION

canMDO


specializeVBO

inINO

oneCDO

orCCO

twoCDO

areasNNSO

ofINO

medicineNNO

andCCO

focusNNO

onINO

theDTO

AmericanJJO

marketNNO
	
..OEßÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1	 	*ORGANIZATION∑

MostJJSO

salesNNSO

ofINO

itsPRP$O

drugsNNSO

overseasRBO

areVBPO

handledVBNO

byINO

theDTO

SwissJJO

drugNNO

makerNNO

RocheNNPORGANIZATION
	
,,O

whichWDTO

isVBZO

theDTO

companyNNO

'sPOSO

majorityNNO

ownerNNO
	
..OE®ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000c70933 *ORGANIZATIONÌ

AsINO

itPRPO

happensVBZO
	
,,O

RocheNNPPERSON

alsoRBO

employsVBZO

herPRP$O

husbandNNO
	
,,O

NickNNPPERSON

HellmannNNPPERSON
	
,,O

anDTO


infectiousJJO

diseaseNNO


specialistNNO
	
,,O

atINO

itsPRP$O

	operationNNO

inINO


PleasantonNNPLOCATION
	
,,O

Calif.NNPLOCATION
	
..O©ÄÄÄ¯ˇˇˇˇ *LOCATIONA™ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000b73fe *LOCATION´ÄÄÄ¯ˇˇˇˇ
 *PERSON?¨ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000c70933 *PERSONç

Dr.NNPPERSON

Desmond-HellmannNNPPERSON
	
,,O

whoWPO

grewVBDO

upRPO

inINO

RenoNNPPERSON
	
,,O

theDTO

secondNNO

ofINO

sevenCDO

childrenNNSO

ofINO


aDTO

pharmacyNNO

ownerNNO
	
,,O

saidVBDO

shePRPO

alwaysRBO

wantedVBDO

toTOO

beVBO


aDTO

doctorNNO
	
..O?≠ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000034782 *PERSONÆÄÄÄ¯ˇˇˇˇ  *PERSON«

ShePRPO

neededVBDO

onlyRBO

threeCDO

yearsNNSO

toTOO

graduateVBO

fromINO

theDTO


UniversityNNPORGANIZATION

ofINORGANIZATION

NevadaNNPORGANIZATION
	
,,O

withINO

straightJJO


ADTO

'sJJO
	
,,O

thenRBO

stayedVBDO

thereRBO

forINO

medicalJJO

schoolNNO

soINO

shePRPO

couldMDO

saveVBO

moneyNNO

byINO

livingVBGO

atINO

homeNNO
	
..OØÄÄÄ¯ˇˇˇˇ	 *ORGANIZATION√

WhenWRBO

shePRPO

wentVBDO

onINO

toTOO

becomeVBO


aDTO

residentNNO

atINO

theDTO


UniversityNNPORGANIZATION

ofINORGANIZATION


CaliforniaNNPORGANIZATION
	
,,O

SanNNPLOCATION

	FranciscoNNPLOCATION
	
,,O

shePRPO

recallsVBZO

beingVBGO

intimidatedVBDO

atINO

firstJJO

byINO

allDTO

theDTO

IvyNNPORGANIZATION

LeaguersNNPORGANIZATION

thereRBO
	
..O∞ÄÄÄ¯ˇˇˇˇ *ORGANIZATIONA±ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000061a55 *LOCATIONE≤ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000003e9cc
 *ORGANIZATIONü

AfterINO

shePRPO

becameVBDO


aDTO

juniorJJO

facultyNNO

memberNNO

atINO

theDTO


universityNNO
	
,,O

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

andCCO

herPRP$O

husbandNNO

uprootedVBDO


themselvesPRPO

toTOO

spendVBO

twoCDO

yearsNNSO

studyingVBGO

transmissionNNO

ofINO

AIDSNNPO

inINO

UgandaNNPLOCATION

andCCO

treatingVBGO

patientsNNSO

thereRBO
	
..O

''''OA≥ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000003e6a2 *LOCATION¥ÄÄÄ¯ˇˇˇˇ *PERSON≥

ItPRPO


completelyRBO

changedVBDO

bothDTO

ofINO

usPRPO
	
,,O

''''O

shePRPO

recalledVBDO
	
..O

''''Oú

ItPRPO

justRBO

madeVBDO

usPRPO

feelVBO

likeINO

thereEXO

'sVBZO

	somethingNNO

aboutINO

havingVBGO

allPDTO

thisDTO

	educationNNO

andCCO

trainingNNO
	
,,O

thatINO

wePRPO

'dMDO

betterRBO

doVBO

	somethingNNO

withINO

itPRPO
	
..O

''''Oö

AfterINO

	returningVBGO

fromINO

AfricaNNPLOCATION

inINO

theDTO

earlyJJO

1990CDO

'sPOSO
	
,,O

shePRPO

openedVBDO


aDTO

privateJJO

oncologyNNO

practiceNNO

inINO

KentuckyNNPLOCATION
	
,,O

herPRP$O

husbandNNO

'sPOSO

nativeJJO

stateNNO
	
..OAµÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000002251d *LOCATIONA∂ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000c70e81 *LOCATION˛

ButCCO

shePRPO

missedVBDO

doingVBGO

researchNNO

andCCO

wasVBDO


frustratedVBNO

byINO

theDTO

dearthNNO

ofINO

cancerNNO


treatmentsNNSO
	
..O

''''Oñ

IPRPO

hatedVBDO

tellingVBGO


aDTO

patientNNO

IPRPO

couldMDO

n'tRBO

thinkVBO

ofINO

	somethingNNO

elseJJO

toTOO

doVBO
	
,,O

''''O

shePRPO

saidVBDO
	
..O¿

-LRB--LRB-O

HerPRP$O

motherNNO

andCCO

olderJJRO

sisterNNO

areVBPO

breastJJO

cancerNNO

	survivorsNNSO
	
,,O

havingVBGO

theDTO

diseaseNNO

beforeINO

	GenentechNNPORGANIZATION

'sPOSO

drugsNNSO

wereVBDO

	availableJJO
	
..O

-RRB--RRB-OE∑ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATIONÌ

SoRBO

whenWRBO

NickNNPPERSON

HellmannNNPPERSON

wasVBDO

offeredVBNO


aDTO

jobNNO

atINO

Bristol-MyersNNPO

SquibbNNPO
	
,,O

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

wentVBDO
	
,,O

tooRBO
	
,,O

workingVBGO

onINO


regulatoryJJO

applicationsNNSO

forINO

TaxolNNPORGANIZATION
	
,,O

theDTO

companyNNO

'sPOSO

bigJJO

cancerNNO

drugNNO
	
..O∏ÄÄÄ¯ˇˇˇˇ *ORGANIZATIONπÄÄÄ¯ˇˇˇˇ *PERSON∫ÄÄÄ¯ˇˇˇˇ *PERSON¡

AfterINO

twoCDO

yearsNNSO

shePRPO

wasVBDO

	recruitedVBNO

byINO

	GenentechNNPORGANIZATION

toTOO

workVBO

onINO


aDTO

platelet-boostingNNO

drugNNO
	
..OEªÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATION∂

ThatDTO

drugNNO

didVBDO

notRBO

succeedVBO
	
,,O

butCCO

herPRP$O

timingNNO

wasVBDO


auspiciousJJO
	
..Oœ

Dr.NNPPERSON

LevinsonNNPPERSON
	
,,O

whoWPO

becameVBDO

chiefJJO

	executiveNNO


aDTO

fewJJO

monthsNNSO

afterINO

herPRP$O

arrivalNNO
	
,,O

wantedVBDO

toTOO

moveVBO

	GenentechNNPORGANIZATION

intoINO

cancerNNO

drugsNNSO
	
..OEºÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATIONΩÄÄÄ¯ˇˇˇˇ  *PERSON·

AndCCO

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

wasVBDO

oneCDO

ofINO

theDTO

fewJJO

oncologistsNNSO

onINO

staffNNO
	
..OæÄÄÄ¯ˇˇˇˇ *PERSONÒ

WithinINO


aDTO

yearNNO

shePRPO

wasVBDO

promotedVBNO

andCCO

putVBNO

inINO

chargeNNO

ofINO

allDTO

clinicalJJO

trialsNNSO
	
..O

''''O≤

IPRPO

promotedVBDO

herPRP$O

veryRBO
	
,,O

veryRBO

quicklyRBO
	
,,O

manyJJO

timesNNSO

overINO
	
,,O

''''O

saidVBDO

Dr.NNPPERSON

LevinsonNNPPERSON
	
,,O

whoWPO

isVBZO


aDTO

researchNNO

	scientistNNO
	
,,O

notRBO


aDTO

	physicianNNO
	
..OøÄÄÄ¯ˇˇˇˇ *PERSON…

HePRPO

citedVBDO

herPRP$O

willingnessNNO

toTOO

workVBO

70CDO

toTOO

80CDO

hoursNNSO


aDTO

weekNNO

andCCO

toTOO

acceptVBO

responsibilityNNO

forINO

successNNO

orCCO

failureNNO
	
,,O

asRBO

wellRBO

asINO

herPRP$O

goodJJO

rapportNNO

withINO

peopleNNSO
	
..OØ

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

concededVBDO

herPRP$O

careerNNO

pathNNO

mightMDO

haveVBO

beenVBNO

moreRBRO

	difficultJJO

ifINO

shePRPO

hadVBDO

childrenNNSO
	
..O¿ÄÄÄ¯ˇˇˇˇ  *PERSONó

ButCCO

shePRPO

saidVBDO

shePRPO

andCCO

herPRP$O

husbandNNO

choseVBDO

notRBO

toTOO

haveVBO

childrenNNSO

forINO

	lifestyleNNO

reasonsNNSO
	
,,O

notRBO

becauseINO

shePRPO

wantedVBDO

toTOO

climbVBO

theDTO

	corporateJJO

ladderNNO
	
..Oº

ShePRPO

runsVBZO

threeCDO

milesNNSO


aDTO

dayNNO
	
,,O

andCCO

shePRPO

andCCO

herPRP$O

husbandNNO

areVBPO

avidJJO

bicycleNNO

ridersNNSO
	
,,O

skiersNNSO

andCCO

hikersNNSO
	
..O¶

WhetherINO

	GenentechNNPORGANIZATION

canMDO

continueVBO

itsPRP$O

winningJJO

streakNNO

withINO

newJJO

drugsNNSO

isVBZO

unclearJJO
	
..OE¡ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATION≤

TheDTO

companyNNO

'sPOSO

nextJJO

thrustNNO

focusesVBZO

onINO

immunologicalJJO

diseasesNNSO
	
..O

''''O‚


ImmunologyNNPO

feelsVBZO

toTOO


aDTO

lotNNO

ofINO

usPRPO

likeINO

oncologyNNPO

didVBDO
	
,,O

''''O

shePRPO

saidVBDO
	
,,O

asINO

newJJO

findingsNNSO

onINO

howWRBO

theDTO

immuneJJO

systemNNO

worksNNSO

areVBPO

openingVBGO

opportunitiesNNSO

forINO

drugNNO

developmentNNO
	
..Oß

SoRBO

farRBO
	
,,O

thoughRBO
	
,,O

theDTO

companyNNO

'sPOSO

trackNNO

recordNNO

inINO

thisDTO

areaNNO

isVBZO

lessRBRO


impressiveJJO

thanINO

inINO

cancerNNO
	
..Oﬁ

XolairNNPO
	
,,O

anDTO

asthmaNNO

drugNNO
	
,,O

isVBZO


innovativeJJO

butCCO

hasVBZO

beenVBNO


aDTO

modestJJO

sellerNNO
	
..Oë

RaptivaNNPPERSON
	
,,O


aDTO

	psoriasisNNO

drugNNO
	
,,O

isVBZO

beingVBGO

beatenVBNO

inINO

theDTO

marketNNO

byINO

EnbrelNNPORGANIZATION

fromINO

AmgenNNPLOCATION
	
..OA¬ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000003ba040 *LOCATION√ÄÄÄ¯ˇˇˇˇ *ORGANIZATIONƒÄÄÄ¯ˇˇˇˇ   *PERSONÓ

	GenentechNNPORGANIZATION

'sPOSO

newJJO

hopeNNO

isVBZO

RituxanNNPLOCATION
	
,,O

itsPRP$O

lymphomaNNO

drugNNO
	
,,O

whichWDTO

hasVBZO

shownVBNO

promiseNNO

inINO

trialsNNSO

asINO


aDTO

	treatmentNNO

forINO


rheumatoidNNO

	arthritisNNO
	
..O≈ÄÄÄ¯ˇˇˇˇ *LOCATIONE∆ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1   *ORGANIZATIONÀ

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

seemsVBZO

anDTO

obviousJJO

	candidateNNO

toTOO


eventuallyRBO

succeedVBO

Dr.NNPPERSON

LevinsonNNPPERSON
	
,,O

whoWPO

isVBZO

55CDO
	
..O«ÄÄÄ¯ˇˇˇˇ	 
*PERSON»ÄÄÄ¯ˇˇˇˇ  *PERSONâ

ButCCO

Dr.NNPPERSON

LevinsonNNPPERSON

saidVBDO

hePRPO

hadVBDO

''VBNO

notRBO

evenRBO

thoughtVBNO

''''O

aboutINO

retiringVBGO
	
,,O

andCCO

Dr.NNPPERSON

Desmond-HellmannNNPPERSON

saidVBDO

shePRPO

didVBDO

notRBO

necessarilyRBO

aspireVBO

toTOO

theDTO

topJJO

jobNNO
	
..O

''''O…ÄÄÄ¯ˇˇˇˇ *PERSON ÄÄÄ¯ˇˇˇˇ *PERSON≤

ItPRPO

'sVBZO

notRBO

onINO

myPRP$O

topJJO

50CDO

listNNO
	
,,O

''''O

shePRPO

saidVBDO
	
..O‰

AndCCO

shePRPO

saysVBZO

thatINO

whenWRBO

shePRPO

hasVBZO

beenVBNO


approachedVBNO

toTOO

runVBO

otherJJO

biotechNNO

	companiesNNSO
	
,,O

shePRPO

hasVBZO

turnedVBNO

theDTO

offersNNSO

downINO
	
..O

''''Oÿ

IfINO

someoneNNO

toldVBDO

mePRPO
	
,,O


```O

WePRPO

'reVBPO

goingVBGO

toTOO

cureVBO

cancerNNO

andCCO

wePRPO

haveVBPO


aDTO

betterJJRO

chanceNNO

thanINO

	GenentechNNPORGANIZATION

'POSO


--:O

firstRBO

ofINO

allDTO

IPRPO

'dMDO

beVBO

reallyRBO

	surprisedVBNO
	
,,O

''''O

shePRPO

saidVBDO
	
,,O

addingVBGO
	
,,O

''''O

MyPRP$O

tankNNO

'sPOSO

beingVBGO

filledVBNO

atINO

	GenentechNNPORGANIZATION
	
..O

''''OEÀÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1, ,*ORGANIZATIONEÃÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000001fc9e1 *ORGANIZATION